Featured Research

from universities, journals, and other organizations

Electroacupuncture Trial Is First Intramural Study Of National Center For Complementary And Alternative Medicine

Date:
June 13, 2002
Source:
NIH/National Center For Complementary And Alternative Medicine
Summary:
The National Center for Complementary and Alternative Medicine (NCCAM) has launched a clinical trial of electroacupuncture to determine if it reduces the delayed nausea experienced by cancer patients following chemotherapy. This study marks the first clinical trial for NCCAM's Division of Intramural Research, which was established in April 2001, at the National Institutes of Health (NIH) in Bethesda, MD.

The National Center for Complementary and Alternative Medicine (NCCAM) has launched a clinical trial of electroacupuncture to determine if it reduces the delayed nausea experienced by cancer patients following chemotherapy. This study marks the first clinical trial for NCCAM's Division of Intramural Research, which was established in April 2001, at the National Institutes of Health (NIH) in Bethesda, MD.

Electroacupuncture, which has been in use for decades, is a variation of traditional acupuncture. In this process, acupuncture needles are placed at selected points and then pulsed with an electric current to stimulate the acupuncture points. Electroacupuncture has been studied for a variety of health conditions including treatment of pain and relief of acute nausea following chemotherapy. Acute nausea occurs within the first 24 hours after chemotherapy, whereas delayed nausea occurs 24 hours to 5 days after chemotherapy.

"The scientific evidence supporting use of electroacupuncture for relief of acute nausea following chemotherapy is very encouraging," said Marc Blackman, M.D., Director of NCCAM's Division of Intramural Research. "Now we need to look at its potential utility for treating delayed post-chemotherapy nausea, a problem for many cancer patients that needs to be investigated."

The randomized trial will enroll 52 patients, aged 16 to 35 years, who have been diagnosed with pediatric sarcomas and are starting their first course of chemotherapy. Standard treatment for pediatric sarcomas involves chemotherapy regimens that are likely to cause both acute and delayed nausea. Patients will be divided into two groups--a treatment group that receives electroacupuncture and a control group that receives sham needling. Sham needling involves placement of acupuncture needles near acupuncture points, but in sites that are considered to have no treatment effect on nausea or emesis (vomiting). The patients and investigators, except for the acupuncturist, will both be masked (double-masked) as to type of treatment provided. Both patient groups will receive standard anti-nausea drugs for treatment of acute nausea and vomiting. Trial results will be expected in approximately 4 years.

"At present, we can treat the acute nausea that accompanies chemotherapy with conventional medications, but delayed nausea is tough to manage," said principal investigator Patrick Mansky, M.D., a research oncologist and staff clinician in NCCAM's Division of Intramural Research. "We hope that this trial will help reveal the value of electroacupuncture in managing delayed chemotherapy-induced nausea as well as other possible benefits."

Unlike acute chemotherapy-induced nausea, delayed nausea does not respond well to medications. To manage delayed nausea, cancer patients are often prescribed glucocorticoids, a type of steroids, which can lead to unwanted side effects, such as weight gain, retarding of growth, or susceptibility to infection. It also appears that delayed nausea may contribute to stress in patients and the negative effects that stress can induce. Therefore, finding an effective alternative may help patients avoid the potential side effects of glucocorticoids and stress.

"Our first intramural clinical trial addresses a significant problem for many cancer patients," said Stephen E. Straus, M.D., NCCAM Director. "If electroacupuncture does reduce delayed nausea following chemotherapy, oncologists will have a treatment option that may spare patients from negative side effects associated with certain medications. This study demonstrates NCCAM's commitment to draw upon the vast research resources and expertise of NIH intramural scientists to assess promising CAM approaches to public health problems."

Studies of both acupuncture and electroacupuncture show that the techniques can be effective for treatment of chemotherapy-induced acute nausea and produce few or no side effects. Trial participants will receive electroacupuncture or sham needling for 7 days (twice daily on days 1 and 2 and once daily on days 3 through 7) starting with the first day of chemotherapy. This will be repeated for a second cycle of chemotherapy. The researchers will followup with patients after two additional cycles of chemotherapy.

Three experienced and licensed acupuncturists, Jay Shah, M.D., Adeline Ge, M.D., and Usha Chaudhry, M.D., of the NIH Clinical Center's Department of Rehabilitation Medicine, will coordinate and perform all of the electroacupuncture and sham needling procedures. Two particular acupuncture points, known as P6 (near the wrist) and St36 (near the knee), have been tested in previous trials for nausea relief and will be employed in this trial. Both patient groups will also have an additional needle placed at a sham point common to both groups to serve as an added control. In addition to determining the effectiveness of electroacupuncture as an approach to treating delayed nausea, the researchers also hope to verify that the specific acupuncture points P6 and St36 are effective for treating delayed nausea.

Patient recruitment for the trial began at the NIH Clinical Center in May 2002. To learn more about this trial, please visit NCCAM's clinical trials page at http://nccam.nih.gov/clinicaltrials.

The National Center for Complementary and Alternative Medicine (NCCAM) is dedicated to exploring complementary and alternative medical (CAM) practices in the context of rigorous science, training CAM researchers, and disseminating authoritative information to the public and professionals. For additional information, call NCCAM's Clearinghouse toll free at 1-888-644-6226, or visit the NCCAM Web site at http://nccam.nih.gov.


Story Source:

The above story is based on materials provided by NIH/National Center For Complementary And Alternative Medicine. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Center For Complementary And Alternative Medicine. "Electroacupuncture Trial Is First Intramural Study Of National Center For Complementary And Alternative Medicine." ScienceDaily. ScienceDaily, 13 June 2002. <www.sciencedaily.com/releases/2002/06/020613075227.htm>.
NIH/National Center For Complementary And Alternative Medicine. (2002, June 13). Electroacupuncture Trial Is First Intramural Study Of National Center For Complementary And Alternative Medicine. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2002/06/020613075227.htm
NIH/National Center For Complementary And Alternative Medicine. "Electroacupuncture Trial Is First Intramural Study Of National Center For Complementary And Alternative Medicine." ScienceDaily. www.sciencedaily.com/releases/2002/06/020613075227.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins